HIV gp160 vaccine (Immuno AG).

被引：0
|
作者：
不详
机构：
来源：
Drugs in R & D | 1999年 / 1卷 / 6期
关键词：
Human Immunodeficiency Virus Type; Gp160 Human Immunodeficiency Virus Type; Gp160 Human Immunodeficiency Virus; Unknown Route; Patient Adverse Effect;
D O I：
10.2165/00126839-199901060-00005
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：449 / 450
页数：1
相关论文
共 50 条
  • [21] THE HIV GLYCOPROTEIN GP160 HAS SUPERANTIGEN-LIKE PROPERTIES
    AKOLKAR, PN
    GULWANIAKOLKAR, B
    CHIRMULE, N
    PAHWA, S
    KALYANARAMAN, VS
    PERGOLIZZI, R
    MACPHAIL, S
    SILVER, J
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 76 (03): : 255 - 265
  • [22] Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration
    Gorse, GJ
    McElrath, MJ
    Matthews, TJ
    Hsieh, RH
    Belshe, RB
    Corey, L
    Frey, SE
    Kennedy, DJ
    Walker, MC
    Eibl, MM
    VACCINE, 1998, 16 (05) : 493 - 506
  • [23] AFFINITY-PURIFIED, OLIGOMERIC HIV-1 GP160 INDUCES BROADLY NEUTRALIZING ANTIBODIES PREFERENTIALLY REACTIVE WITH NATIVE GP120/GP160
    VANCOTT, TC
    KAMINSKI, R
    MASCOLA, J
    KALYANARAMAN, V
    COX, J
    POLONIS, V
    VEIT, S
    ETTORE, C
    HALLBERG, P
    PATEL, L
    LOWELL, G
    BURKE, D
    RECHTMAN, D
    BIRX, D
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 : S150 - S150
  • [24] Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine
    Lambert, JS
    Viscidi, R
    Walker, MC
    Clayman, B
    Winget, M
    Wolff, M
    Schwartz, DH
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (03) : 302 - 308
  • [25] A PHASE-I TRIAL OF A RECOMBINANT GP160 CANDIDATE AIDS VACCINE
    KOVACS, JA
    MEGIL, ME
    DEYTON, L
    METCALF, JA
    SALZMAN, N
    VASUDEVACHARI, M
    BASELER, M
    MARTIN, M
    FOLKS, T
    COCHRAN, M
    SMITH, G
    VOLVOVITZ, F
    MASUR, H
    FAUCI, AS
    LANE, HC
    CLINICAL RESEARCH, 1988, 36 (03): : A460 - A460
  • [26] The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160
    Sen, Jayita
    Jacobs, Amy
    Jiang, Haiqing
    Rong, Lijun
    Caffrey, Michael
    PROTEIN SCIENCE, 2007, 16 (06) : 1236 - 1241
  • [27] CHARACTERIZATION OF SERUM ANTIBODY-RESPONSES TO RECOMBINANT HIV-1 GP160 VACCINE BY ENZYME-IMMUNOASSAY
    VISCIDI, R
    ELLERBECK, E
    GARRISON, L
    MIDTHUN, K
    CLEMENTS, ML
    CLAYMAN, B
    FERNIE, B
    SMITH, G
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (11) : 1251 - 1256
  • [28] Phase I Clinical Trial with HIV-1 gp160 Plasmid Vaccine in HIV-1-Infected Asymptomatic Subjects
    R. Weber
    W. Bossart
    R. Cone
    R. Luethy
    K. Moelling
    European Journal of Clinical Microbiology & Infectious Diseases, 2001, 20 : 800 - 803
  • [29] Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects
    Weber, R
    Bossart, W
    Cone, R
    Luethy, R
    Moelling, K
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (11) : 800 - 803
  • [30] ANTIBODIES TO RECOMBINANT GP160 IN MUCOSAL SECRETIONS AND SERA OF PERSONS INFECTED WITH HIV-1 AND SERONEGATIVE VACCINE RECIPIENTS
    FUNKHOUSER, A
    CLEMENTS, ML
    SLOME, S
    CLAYMAN, B
    VISCIDI, R
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (07) : 627 - 632
12345